About
Our Story
→
With BUZUD CGM, you can make treatment decisions without relying on a blood glucose (BG) meter.However, until you are fully confident in using the CGM, it's recommended to continue using a meter—especially in special situations or when glucose levels are changing rapidly.Do not rush the transition. It may take days, weeks, or even longer for you to feel comfortable using CGM data to guide treatment decisions.Work closely with your healthcare professional to regularly review your CGM readings and physical symptoms to determine what works best for you.When Can You Use BUZUD CGM for Treatment Decisions?You can use BUZUD CGM data for treatment decisions when you see both a glucose value and a trend steady arrow displayed on the BUZUD app home screen.BUZUD CGM uses arrows to indicate the direction and speed of glucose changes. The meaning of each trend arrow is as follows:When Should You Use a Blood Glucose Meter?When no glucose value or trend arrow appears in the BUZUD appWhen your physical symptoms do not match the CGM reading (e.g., you feel dizzy or sweaty, but CGM shows a normal value)In these cases, use your blood glucose meter and rely on that reading for any treatment decisions.When Should You Watch and Wait?Avoid taking multiple insulin doses too close together (known as "insulin stacking")Wait at least 2 hours between insulin dosesIf a rapid change is shown in the trend arrows, or after a recent dose or meal, it's best to monitor the trend before making further adjustmentsIf you are unsure about a reading or do not feel well, consult your doctor or contact BUZUD support for assistance.
1. BackgroundWith the widespread adoption of Continuous Glucose Monitoring (CGM) systems in diabetes management, their technical limitations have become increasingly evident. A common artifact seen in clinical practice is compression-induced false hypoglycemia, commonly referred to as “compression low.” This typically occurs at night, presenting as low glucose alarms from CGM devices without symptoms or confirmation via capillary blood glucose testing.This white paper aims to systematically analyze the mechanism, brand-specific differences, clinical identification, and management strategies of compression low based on published studies and manufacturer documentation, to help medical professionals enhance their ability to interpret CGM data anomalies.2. Definition and Clinical ManifestationsCompression-induced false hypoglycemia refers to the inaccurate low glucose readings detected by CGM sensors under mechanical pressure (e.g., lying on the sensor during sleep), due to impaired interstitial fluid flow at the sensor site.Common clinical signs include:Sudden drop and rapid recovery patterns on CGM curves during nighttime;Absence of typical hypoglycemia symptoms;Discrepancy between CGM readings and capillary blood glucose values;Sensor readings normalize after pressure is relieved.3. Mechanisms1. Restricted Interstitial Fluid PerfusionCGM sensors measure glucose concentration in interstitial fluid, not directly in blood. External pressure reduces local capillary perfusion and slows interstitial fluid exchange, leading to artificially low readings.2. Extended Lag EffectAfter pressure is relieved, glucose recovery in the interstitial fluid takes time. This physiological lag causes continued falsely low readings even after the compression is gone.3. Probe DisplacementMechanical force may alter the insertion angle or depth of the sensor probe, shifting it to a low-perfusion or non-target area, thus compromising signal reliability.4. Clinical Evidence and FrequencyKey Studies:Mensh BD, 2013, J Diabetes Sci Technol: Demonstrated significantly increased false low risk from sleeping on the sensor.Facchinetti A, 2016, Diabetes Technol Ther: Found that median compression low events lasted ~45 minutes (range 30–70 mins) in Dexcom G4 users, mostly occurring at night.Helton J, 2011: Modeled CGM errors based on interstitial fluid dynamics and first proposed compression-perfusion interplay as a mechanism.Frequency Observations:Nighttime is a high-risk period, especially during prolonged sleep in one position;Sensors worn for longer durations, with poor fixation or improper adhesion, are more prone to this artifact;Most users may encounter 1–3 compression low events during a typical 7-day CGM cycle.5. Brand-Specific DifferencesDexcomOfficial documentation explicitly acknowledges compression lows;Recommends sensor placement in low-pressure areas (e.g., lateral abdomen, back of the upper arm);G6/G7 systems offer faster recovery but cannot completely eliminate the issue.Abbott FreeStyle LibreThe user manual does not explicitly define compression low, but highlights that sensor dislodgement or poor adhesion can cause falsely low readings;Clinical reports indicate Libre 2/3 sensors are more susceptible, especially in lean individuals.Medtronic Guardian SensorAdvises against sensor placement in areas prone to motion or compression;Compression-induced errors may falsely trigger SmartGuard automatic insulin suspension, affecting insulin delivery.Senseonics Eversense (Implantable CGM)As a fully implantable sensor, Eversense is largely immune to external pressure effects;No reported cases of compression lows, making it unique among CGM systems.BUZUD CGMBUZUD uses a subcutaneous sensor structure similar to traditional CGMs, supporting real-time glucose monitoring;Preliminary testing shows improved resistance to compression-related signal artifacts due to enhanced stability and adhesion;Compression lows may still occur; BUZUD advises avoiding sensor placement in areas likely to be compressed during sleep;If abnormal readings occur, users are encouraged to confirm via capillary blood glucose testing.6. Clinical Management RecommendationsIdentification Criteria:CGM curve shows sudden drop with rapid rebound, inconsistent with true hypoglycemia;No symptoms of hypoglycemia present;Strong correlation with sleep position or pressure on the sensor area.Response Strategies:Educate patients to choose sensor sites unlikely to be compressed while lying down;Do not immediately treat CGM-reported lows with carbohydrates—verify with fingerstick first;Label these events in medical records as “compression-induced artifacts” to avoid misdiagnosis or overtreatment;If frequently recurring, reassess adhesion method and device stability, and contact manufacturer if needed;Encourage CGM manufacturers to optimize algorithms that detect compression-related patterns to reduce false alarms.7. ConclusionCompression-induced false hypoglycemia is a CGM-specific artifact that poses challenges to accurate diabetes management. Its relatively frequent occurrence and potential clinical impact necessitate better understanding among healthcare providers.By improving clinical recognition, educating users on proper placement and sleep behavior, and working with device manufacturers to enhance signal processing, the burden of this artifact on clinical decision-making can be significantly reduced.It is recommended that all diabetes care teams include this topic in CGM interpretation training to strengthen understanding of device limitations and improve patient outcomes.
Time in Range (TIR) refers to the percentage of time that a person's glucose levels stay within a defined target range. It is a key indicator for assessing the quality of glucose control, typically based on data collected from continuous glucose monitoring (CGM) devices.TIR reflects the proportion of time that glucose levels fall into three general categories:Target Range: 3.9–10.0 mmol/LVery High: Above 13.9 mmol/LVery Low: Below 3.0 mmol/LThese thresholds are based on international clinical consensus, but doctors may adjust them according to individual needs.Why is TIR important?TIR provides a more dynamic view of daily glucose control than A1C alone.Maintaining a higher TIR (e.g., above 70%) is associated with reduced risk of complications.TIR is useful for evaluating treatment effectiveness, medication response, or lifestyle changes.TIR is becoming a standard metric in diabetes management and supports more personalized, real-time care.
The Ambulatory Glucose Profile (AGP) is a standardized glucose report developed and licensed by the International Diabetes Center (IDC).The AGP report compiles continuous glucose monitoring (CGM) data over a period of time to provide a comprehensive overview of glucose trends, offering a big-picture view of diabetes management.It is important to note that the AGP is just one tool for understanding glucose patterns. It should be interpreted in combination with lifestyle, medication use, and other medical information.
If you're already familiar with Continuous Glucose Monitoring (CGM) systems, using the BUZUD CGM may or may not significantly change your daily routine.However, if you’ve never used a CGM before, the BUZUD CGM can offer meaningful improvements over traditional blood glucose monitoring methods like finger pricks.Benefits of Using BUZUD CGM:See not just your current glucose value, but also the trend — whether it’s rising, falling, or stable.Gain immediate feedback on how your lifestyle choices (e.g., food, activity, stress) affect your glucose.Make treatment decisions using BUZUD CGM readings, such as adjusting insulin or food intake.Reduce the pain and inconvenience of frequent fingersticks, helping to protect your fingertips.If your glucose readings or alerts from BUZUD CGM do not match how you feel or what you expect, use a blood glucose meter to make treatment decisions.
Blood glucose (sugar) levels vary depending on the time of day, food intake, and individual health conditions. The chart below shows target glucose ranges at different times of the day, which can help you and your healthcare provider develop a personalized monitoring plan.Time of CheckTarget Range (No Diabetes)Target Range (With Diabetes)Before breakfast (fasting)< 5.6 mmol/L3.9 – 7.2 mmol/LBefore lunch, dinner, snack< 6.1 mmol/L3.9 – 7.2 mmol/LTwo hours after meals< 7.8 mmol/L< 10 mmol/LBedtime< 6.7 mmol/L5.0 – 8.3 mmol/LHbA1c (Glycated Hemoglobin)< 5.5%< 7%Note: Your personal targets may vary and should be set by your healthcare provider based on your individual condition.
Time in Range (TIR) refers to the percentage of time that glucose levels fall within specific categories—low, target, or high—over a given period. This metric is calculated based on glucose readings collected from a continuous glucose monitoring (CGM) system.Each glucose reading is evaluated against a predefined target range and categorized as one of the following:In Range: Glucose is within the target range.High: Glucose is above the upper limit of the target range.Low: Glucose is below the lower limit of the target range.Urgent Low: Glucose is extremely low and considered dangerous.The system counts the number of readings in each category and calculates the percentage of time spent in each range. TIR reports may also distinguish between daytime and nighttime periods to provide a more detailed view of glucose patterns.This approach helps assess overall glucose control and supports better treatment decisions.
Blood sugar levels naturally fluctuate throughout the day, and occasional highs and lows are common. According to common clinical guidelines in Singapore, the target blood glucose range before meals or during fasting is typically 4.0 to 7.0 mmol/L.Two hours after a meal, it's normal for glucose levels to rise. The recommended post-meal range is usually 5.0 to 10.0 mmol/L. If your A1C targets are not being met, your doctor may advise keeping post-meal glucose within 5.0 to 8.0 mmol/L to improve overall glycemic control.Morning Blood Glucose LevelsMorning glucose levels may be slightly lower, as the body has been fasting overnight and activity levels are low. After breakfast, glucose levels generally rise back into the normal range.If your morning readings are consistently too high or too low, consult your doctor for advice on how to adjust your treatment or lifestyle to stay within your target range.Note: Your target glucose range should be set by your healthcare provider based on your individual health condition.
Glucose Management Indicator (GMI) is a value calculated from continuous glucose monitoring (CGM) data that estimates the A1C level you might expect from a laboratory test.GMI is derived from the average glucose measured over at least 12 days of CGM use. The result is often close to the lab-measured A1C but may also be slightly higher or lower.Differences between GMI and laboratory A1C may be caused by:Individual variations in red blood cell lifespanDifferences in how glucose binds to hemoglobinRecent changes in glucose controlGMI is a helpful indicator of recent glucose trends but is not a direct replacement for lab-measured A1C.
The HbA1C test, also known as the glycosylated hemoglobin test, is an important blood test used to evaluate how well diabetes is being managed. It reflects the average blood glucose level over the past few months. For individuals without diabetes, a normal HbA1C level typically falls between 4% and 6%. Your doctor will determine the ideal HbA1C target range based on your individual condition.The higher the HbA1C level, the greater the risk of complications such as heart disease, stroke, and neuropathy. Therefore, keeping your blood glucose and HbA1C levels within the target range can significantly reduce the risk of these health problems.
In Continuous Glucose Monitoring (CGM), eHbA1C stands for estimated HbA1C, and it differs from the actual lab-measured HbA1C in several ways:Comparison TableItemHbA1C (Lab Test)eHbA1C (Estimated)SourceMeasured through a blood test in a labCalculated by the CGM system from glucose dataTime SpanReflects average blood glucose over 2–3 monthsBased on recent days or weeks of CGM dataAccuracyClinical standard, widely acceptedApproximate value, affected by device and algorithmNameHbA1C (Glycohemoglobin A1C)eHbA1C (Estimated A1C), also known as GMIKey NoteseHbA1C is an estimate, useful for tracking glucose trends, but it should not replace lab-tested HbA1C.Some CGM systems refer to eHbA1C as GMI (Glucose Management Indicator), which serves a similar purpose.SummaryeHbA1C provides an estimated A1C value based on CGM data. While helpful for ongoing glucose management, it is not as precise as laboratory HbA1C tests. Both can be used together to better understand and manage blood glucose control.
Diabetes mellitus is a chronic metabolic condition that results from problems related to insulin. It includes both type 1 and type 2 diabetes, but the causes and mechanisms behind each type are different.In type 1 diabetes, the body's immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body cannot produce enough insulin to regulate blood glucose levels. Experts believe that the development of type 1 diabetes is due to a combination of genetic factors and environmental triggers, such as viral infections, which may provoke an abnormal immune response.In type 2 diabetes, the body becomes resistant to insulin. To compensate, the pancreas produces more insulin, but over time, this demand leads to pancreatic “burnout” and a gradual decline in insulin production. Type 2 diabetes is influenced by multiple factors, including genetics, being overweight, physical inactivity, and having a family history of the condition. People with insulin resistance or a family history of diabetes are at higher risk.Comparison of Type 1 and Type 2 DiabetesCategoryType 1 DiabetesType 2 DiabetesCauseImmune system destroys insulin-producing beta cellsInsulin resistance and eventual decline in insulin productionInsulin ProductionVery low or noneInitially high or normal, then declines over timeInsulin DependenceYes, lifelong insulin therapy is requiredNot always; may be managed with lifestyle or oral medication initiallyCommon Onset AgeUsually childhood or adolescenceTypically adulthood, but increasingly seen in younger agesOnset SpeedSuddenGradual, often detected during routine check-upsAssociation with WeightNot directly related to body weightStrongly associated with overweight or obesityGenetic InfluenceSome genetic predispositionStrong genetic link and family history riskPreventabilityCurrently not preventableCan often be prevented or delayed with healthy lifestyleUnderstanding the differences between type 1 and type 2 diabetes helps guide diagnosis, treatment, and lifestyle strategies for long-term management.
You may have come across different terms for diabetes, such as “mellitus” and “insipidus.” While they sound similar, they refer to two very different medical conditions. Here's a quick explanation:What Is Diabetes Mellitus?Diabetes mellitus is the condition most people refer to when they say "diabetes." It includes:Type 1 diabetes: The body does not produce enough insulin to regulate blood glucose.Type 2 diabetes: The body becomes resistant to insulin. To compensate, the pancreas produces more insulin, which over time leads to pancreatic “burnout” and decreased insulin production.The majority of people with diabetes have diabetes mellitus, which includes both type 1 and type 2 forms.What Is Diabetes Insipidus?Diabetes insipidus is a rare condition that is unrelated to blood glucose levels. People with this condition usually have normal blood sugar, but their kidneys are unable to properly concentrate urine. As a result, the body loses excessive water, leading to frequent urination, intense thirst, and dehydration.Diabetes insipidus may be caused by:Genetic factorsMajor surgery or traumaCertain medications that affect kidney functionIn Summary:Diabetes mellitus is related to insulin and blood sugar regulation.Diabetes insipidus is related to kidney function and water balance, not glucose.Sources:National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes InsipidusWhat Is Diabetes
